Recursion

Recursion is a clinical-stage biotechnology company using AI and robotic wet-lab automation to industrialise small molecule drug discovery.

Its platform integrates phenomics, transcriptomics, proteomics and patient data to identify and optimise drug candidates at scale.

Following its acquisition of Oxford-based Exscientia in November 2024, Recursion's UK operations serve as its primary European R&D base. Pharmaceutical partners include Roche, Sanofi and Bayer.